A Blood-Brain Barrier (BBB) Disrupter Is Also a Potent α-Synuclein (α-syn) Aggregation Inhibitor
| Autor: | Moran Frenkel-Pinter, Christina Patrick, Edward Rockenstein, Nirit Egoz-Matia, Daniel L. Segal, Eliezer Masliah, Ehud Gazit, Ronit Shaltiel-Karyo, Michal Levy-Sakin, Abigail Schiller |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Alpha-synuclein
Genetically modified mouse Amyloid Cell Biology Pharmacology Biology Blood–brain barrier Biochemistry Neuroprotection nervous system diseases chemistry.chemical_compound medicine.anatomical_structure chemistry In vivo medicine Mannitol Chemical chaperone Molecular Biology medicine.drug |
| Zdroj: | Journal of Biological Chemistry. 288:17579-17588 |
| ISSN: | 0021-9258 |
| DOI: | 10.1074/jbc.m112.434787 |
| Popis: | The development of disease-modifying therapy for Parkinson disease has been a main drug development challenge, including the need to deliver the therapeutic agents to the brain. Here, we examined the ability of mannitol to interfere with the aggregation process of α-synuclein in vitro and in vivo in addition to its blood-brain barrier-disrupting properties. Using in vitro studies, we demonstrated the effect of mannitol on α-synuclein aggregation. Although low concentration of mannitol inhibited the formation of fibrils, high concentration significantly decreased the formation of tetramers and high molecular weight oligomers and shifted the secondary structure of α-synuclein from α-helical to a different structure, suggesting alternative potential pathways for aggregation. When administered to a Parkinson Drosophila model, mannitol dramatically corrected its behavioral defects and reduced the amount of α-synuclein aggregates in the brains of treated flies. In the mThy1-human α-synuclein transgenic mouse model, a decrease in α-synuclein accumulation was detected in several brain regions following treatment, suggesting that mannitol promotes α-synuclein clearance in the cell bodies. It appears that mannitol has a general neuroprotective effect in the transgenic treated mice, which includes the dopaminergic system. We therefore suggest mannitol as a basis for a dual mechanism therapeutic agent for the treatment of Parkinson disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|